Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line

Fluids and Barriers of the CNS

Luca Cucullo²  Shikha Prasad¹  Ravi K Sajja¹ 

[1] Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 S. Coulter Street, Amarillo, TX 79106, USA;Center for Blood Brain Barrier Research, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA

关键词: Alternative;    Cytokine;    Inflammation;    Blood-brain barrier;    Tight junctions;    Permeability;    Oxidative stress;    Glucose transporter;    hCMEC/D3 cell line;    Diabetes;   

Others  :  802308
DOI  :  10.1186/2045-8118-11-8

 received in 2013-12-18, accepted in 2014-03-17,  发布年份 2014

【 摘 要 】

Background

Cerebrovascular complications involving endothelial dysfunction at the blood-brain barrier (BBB) are central to the pathogenesis of diabetes-related CNS disorders. However, clinical and experimental studies have reported contrasting evidence in relation to the effects of hyperglycemia on BBB permeability and function. Similarly the effect of hypoglycemia on BBB integrity is not well understood. Therefore, we assessed the differential impact of hypo and hyperglycemic conditions on BBB integrity and endothelial function in vitro using hCMEC/D3, a well characterized human brain microvascular endothelial cell line.

Methods

Parallel monolayers of hCMEC/D3 were exposed to normal, hypo- or hyperglycemic media, containing 5.5, 2.2 or 35 mM D-glucose, respectively. Following 3-24h exposure, the expression and distribution of BBB tight junction (ZO-1 and claudin-5) adherence junction (VE-cadherin) proteins, and glucose transporters as well as inflammatory (VCAM-1) and oxidative stress (Nrf-2) markers were analyzed by immunofluorescence and western blotting. Endothelial release of growth factors and pro-inflammatory cytokines were determined by ELISA. Further, the impact of altered glycemia on BBB permeability was assessed in hCMEC/D3 – astrocyte co-cultures on Transwell supports using fluorescent dextrans (4–70 kDa).

Results

Compared to controls, exposure to hypoglycemia (3 and 24h) down-regulated the expression of claudin-5 and disrupted the ZO-1 localization at cell-cell contacts, while hyperglycemia marginally reduced claudin-5 expression without affecting ZO-1 distribution. Permeability to dextrans (4-10 kDa) and VEGF release at 24h were significantly increased by hypo- and hyperglycemia, although 70 kDa dextran permeability was increased only under hypoglycemic conditions. The expression of SGLT-1 was up-regulated at 24h hypoglycemic exposure while only a modest increase of GLUT-1 expression was observed. In addition, the expression of Nrf-2 and release of interleukin-6 and PDGF-BB, were down-regulated by hypoglycemia (but not hyperglycemia), while both conditions induced a marginal and transient increase in VCAM-1 expression from 3 to 24h, including a significant increase in VE-cadherin expression at 3 h following hyperglycemia.

Conclusions

In summary, our findings demonstrate a potential impairment of BBB integrity and function by hypo or hyperglycemia, through altered expression/distribution of TJ proteins and nutrient transporters. In addition, hypoglycemic exposure severely affects the expression of oxidative and inflammatory stress markers of BBB endothelium.

【 授权许可】

   
2014 Sajja et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Abbott NJ: Blood–brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013, 36:437-449.
• [2]Hawkins BT, Davis TP: The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
• [3]Wolburg H, Lippoldt A: Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
• [4]Agarwal N, Lippmann ES, Shusta EV: Identification and expression profiling of blood–brain barrier membrane proteins. J Neurochem 2010, 112:625-635.
• [5]Pardridge WM: Blood–brain barrier genomics. Stroke 2007, 38:686-690.
• [6]Zlokovic BV: The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
• [7]Horani MH, Mooradian AD: Effect of diabetes on the blood brain barrier. Curr Pharm Des 2003, 9:833-840.
• [8]Serlin Y, Levy J, Shalev H: Vascular pathology and blood–brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011, 2011:609202.
• [9]Huber JD, Vangilder RL, Houser KA: Streptozotocin-induced diabetes progressively increases blood–brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 2006, 291:H2660-H2668.
• [10]Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS: Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 2005, 54:2977-2982.
• [11]Dai J, Vrensen GF, Schlingemann RO: Blood–brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res 2002, 954:311-316.
• [12]Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I: Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003, 74:70-76.
• [13]Kumagai AK, Kang YS, Boado RJ, Pardridge WM: Upregulation of blood–brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 1995, 44:1399-1404.
• [14]Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, Feng B, Li C, Feuerstein TJ, Gibbs J, Smith B, de Morais SM, Dower WJ, Koller KJ: Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009, 59:404-413.
• [15]Naik P, Cucullo L: In vitro blood–brain barrier models: current and perspective technologies. J Pharm Sci 2012, 101:1337-1354.
• [16]Cucullo L, Couraud PO, Weksler B, Romero IA, Hossain M, Rapp E, Janigro D: Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab 2008, 28:312-328.
• [17]Hatherell K, Couraud PO, Romero IA, Weksler B, Pilkington GJ: Development of a three-dimensional, all-human in vitro model of the blood–brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods 2011, 199:223-229.
• [18]Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO: Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 1872–1874, 2005:19.
• [19]Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO: Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 2012, 9:23. BioMed Central Full Text
• [20]Weksler B, Romero IA, Couraud PO: The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 2013, 10:16. BioMed Central Full Text
• [21]Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J: The human brain endothelial cell line hCMEC/D3 as a human blood–brain barrier model for drug transport studies. J Neurochem 2008, 107:1358-1368.
• [22]Cowan KM, Easton AS: Neutrophils block permeability increases induced by oxygen glucose deprivation in a culture model of the human blood–brain barrier. Brain Res 2010, 1332:20-31.
• [23]Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L: Side by side comparison between dynamic versus static models of blood–brain barrier in vitro: a permeability study. Brain Res 2006, 1109:1-13.
• [24]Yan J, Zhang Z, Shi H: HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci 2012, 69:115-128.
• [25]Kemeny SF, Figueroa DS, Clyne AM: Hypo- and hyperglycemia impair endothelial cell actin alignment and nitric oxide synthase activation in response to shear stress. PLoS One 2013, 8:e66176.
• [26]Rapoport SI: Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000, 20:217-230.
• [27]Sajja RK, Rahman S: Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of DeltaFosB in mice. Alcohol 2013, 47:299-307.
• [28]Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim KW: SSeCKS regulates angiogenesis and tight junction formation in blood–brain barrier. Nat Med 2003, 9:900-906.
• [29]Alfieri A, Srivastava S, Siow RC, Modo M, Fraser PA, Mann GE: Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 2011, 589:4125-4136.
• [30]Sandberg M, Patil J, D'Angelo B, Weber SG, Mallard C: NRF2-regulation in brain health and disease: Implication of cerebral inflammation. Neuropharmacology 2014, 79C:298-306.
• [31]Fasler-Kan E, Suenderhauf C, Barteneva N, Poller B, Gygax D, Huwyler J: Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3. Brain Res 2010, 1354:15-22.
• [32]Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, Potente M, Daly C, Dimmeler S, Dejana E: Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 2008, 10:923-934.
• [33]Krewski D, Acosta D Jr, Andersen M, Anderson H, Bailar JC III, Boekelheide K, Brent R, Charnley G, Cheung VG, Green S Jr, Kelsey KT, Kerkvliet NI, Li AA, McCray L, Meyer O, Patterson RD, Pennie W, Scala RA, Solomon GM, Stephens M, Yager J, Zeise L: Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 2010, 13:51-138.
• [34]Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A: Differences in amyloid-beta clearance across mouse and human blood–brain barrier models: Kinetic analysis and mechanistic modeling. Neuropharmacology 2014, 79C:668-678.
• [35]Tai LM, Reddy PS, Lopez-Ramirez MA, Davies HA, Male DK, Loughlin AJ, Romero IA: Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. Brain Res 2009, 1292:14-24.
• [36]Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM, Couraud PO, Kubo Y, Tachikawa M, Terasaki T: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood–brain barrier model. Mol Pharm 2013, 10:289-296.
• [37]Luissint AC, Federici C, Guillonneau F, Chretien F, Camoin L, Glacial F, Ganeshamoorthy K, Couraud PO: Guanine nucleotide-binding protein Galphai2: a new partner of claudin-5 that regulates tight junction integrity in human brain endothelial cells. J Cereb Blood Flow Metab 2012, 32:860-873.
• [38]Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR: VEGF-mediated disruption of endothelial CLN-5 promotes blood–brain barrier breakdown. Proc Natl Acad Sci U S A 1977–1982, 2009:106.
• [39]Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S: Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice. J Cell Biol 2003, 161:653-660.
• [40]Chehade JM, Haas MJ, Mooradian AD: Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. Neurochem Res 2002, 27:249-252.
• [41]Fischer S, Wobben M, Marti HH, Renz D, Schaper W: Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 2002, 63:70-80.
• [42]El-Remessy AB, Franklin T, Ghaley N, Yang J, Brands MW, Caldwell RB, Behzadian MA: Diabetes-Induced Superoxide Anion and Breakdown of the Blood-Retinal Barrier: Role of the VEGF/uPAR Pathway. PLoS One 2013, 8:e71868.
• [43]Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD: Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007, 50:202-211.
• [44]Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA, Wylezinska-Arridge M, Couraud PO, Lopez-Tremoleda J, Christian HC, Weksler BB, Malaspina A, Solito E: Identification of an essential endogenous regulator of blood–brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci U S A 2013, 110:832-841.
• [45]Vannucci SJ, Clark RR, Koehler-Stec E, Li K, Smith CB, Davies P, Maher F, Simpson IA: Glucose transporter expression in brain: relationship to cerebral glucose utilization. Dev Neurosci 1998, 20:369-379.
• [46]Pardridge WM, Triguero D, Farrell CR: Downregulation of blood–brain barrier glucose transporter in experimental diabetes. Diabetes 1990, 39:1040-1044.
• [47]Duelli R, Maurer MH, Staudt R, Heiland S, Duembgen L, Kuschinsky W: Increased cerebral glucose utilization and decreased glucose transporter Glut1 during chronic hyperglycemia in rat brain. Brain Res 2000, 858:338-347.
• [48]Hou WK, Xian YX, Zhang L, Lai H, Hou XG, Xu YX, Yu T, Xu FY, Song J, Fu CL, Zhang WW, Chen L: Influence of blood glucose on the expression of glucose trans-porter proteins 1 and 3 in the brain of diabetic rats. Chin Med J (Engl) 2007, 120:1704-1709.
• [49]Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ, Smith QR: Blood–brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem 1999, 72:238-247.
• [50]Abdul Muneer PM, Alikunju S, Szlachetka AM, Murrin LC, Haorah J: Impairment of brain endothelial glucose transporter by methamphetamine causes blood–brain barrier dysfunction. Mol Neurodegener 2011, 6:23. BioMed Central Full Text
• [51]McCall AL, van Bueren AM, Huang L, Stenbit A, Celnik E, Charron MJ: Forebrain endothelium expresses GLUT4, the insulin-responsive glucose transporter. Brain Res 1997, 744:318-326.
• [52]Ngarmukos C, Baur EL, Kumagai AK: Co-localization of GLUT1 and GLUT4 in the blood–brain barrier of the rat ventromedial hypothalamus. Brain Res 2001, 900:1-8.
• [53]Meireles M, Martel F, Araujo J, Santos-Buelga C, Gonzalez-Manzano S, Duenas M, de Freitas V, Mateus N, Calhau C, Faria A: Characterization and modulation of glucose uptake in a human blood–brain barrier model. J Membr Biol 2013, 246:669-677.
• [54]Nishizaki T, Matsuoka T: Low glucose enhances Na+/glucose transport in bovine brain artery endothelial cells. Stroke 1998, 29:844-849.
• [55]Vemula S, Roder KE, Yang T, Bhat GJ, Thekkumkara TJ, Abbruscato TJ: A functional role for sodium-dependent glucose transport across the blood–brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther 2009, 328:487-495.
• [56]Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
• [57]Singh P, Jain A, Kaur G: Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem 2004, 260:153-159.
• [58]Tsuruta R, Fujita M, Ono T, Koda Y, Koga Y, Yamamoto T, Nanba M, Shitara M, Kasaoka S, Maruyama I, Yuasa M, Maekawa T: Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Brain Res 2010, 1309:155-163.
• [59]Coisne C, Engelhardt B: Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal 2011, 15:1285-1303.
• [60]Lehner C, Gehwolf R, Tempfer H, Krizbai I, Hennig B, Bauer HC, Bauer H: Oxidative stress and blood–brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal 2011, 15:1305-1323.
• [61]Freeman LR, Keller JN: Oxidative stress and cerebral endothelial cells: regulation of the blood–brain-barrier and antioxidant based interventions. Biochim Biophys Acta 1822, 2012:822-829.
• [62]Okouchi M, Okayama N, Alexander JS, Aw TY: NRF2-dependent glutamate-L-cysteine ligase catalytic subunit expression mediates insulin protection against hyperglycemia- induced brain endothelial cell apoptosis. Curr Neurovasc Res 2006, 3:249-261.
• [63]Zhao J, Moore AN, Redell JB, Dash PK: Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J Neurosci 2007, 27:10240-10248.
• [64]Tsai HY, Huang PH, Lin FY, Chen JS, Lin SJ, Chen JW: Ginkgo biloba extract reduces high-glucose-induced endothelial reactive oxygen species generation and cell adhesion molecule expression by enhancing HO-1 expression via Akt/eNOS and p38 MAP kinase pathways. Eur J Pharm Sci 2013, 48:803-811.
• [65]Wruck CJ, Streetz K, Pavic G, Gotz ME, Tohidnezhad M, Brandenburg LO, Varoga D, Eickelberg O, Herdegen T, Trautwein C, Cha K, Kan YW, Pufe T: Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. J Biol Chem 2011, 286:4493-4499.
• [66]Lopez-Ramirez MA, Male DK, Wang C, Sharrack B, Wu D, Romero IA: Cytokine-induced changes in the gene expression profile of a human cerebral microvascular endothelial cell-line, hCMEC/D3. Fluids Barriers CNS 2013, 10:27. BioMed Central Full Text
• [67]Hoffman WH, Stamatovic SM, Andjelkovic AV: Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res 2009, 1254:138-148.
• [68]Winkler EA, Bell RD, Zlokovic BV: Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener 2010, 5:32. BioMed Central Full Text